Literature DB >> 30093110

LncRNA snaR upregulates GRB2-associated binding protein 2 and promotes proliferation of ovarian carcinoma cells.

Yiping Huang1, Yingying Hu2, Zujian Jin2, Zhaojun Shen2.   

Abstract

BACKGROUND: The functionality of lncRNA snaR has only been characterized in breast cancer and colon cancer. The aim of the current study is to explore the involvement of lncRNA snaR in ovarian carcinoma (OC).
MATERIALS AND METHODS: Expression of lncRNA snaR and GRB2-associated binding protein 2 (GAB2) in plasma of both patients with OC and healthy females was detected by qRT-PCR. Application value of plasma lncRNA snaR in the diagnosis of OC was evaluated by ROC analysis. Correlation between plasma lncRNA snaR and GAB2 was analyzed by Pearson correlation coefficient. LncRNA snaR and GAB2 expression vectors as well as GAB2 siRNA were transfected into cells of human OC cell lines, and the effect on lncRNA snaR expression, GAB2 expression and cell proliferation was detected by qRT-PCR, western blot and CCK-8 assay.
RESULTS: It was observed that plasma levels of lncRNA snaR and GAB2 were significantly higher in OC patients than those in healthy controls. In effect, high levels of plasma lncRNA snaR and GAB2 distinguished OC patients from healthy controls. Plasma lncRNA snaR and GAB2 were positively correlated in OC patients but not in healthy controls. LncRNA snaR overexpression promoted cancer cell proliferation and upregulated GAB2 expression.
CONCLUSIONS: GAB2 overexpression also promoted cancer cell proliferation but showed no significant effects on lncRNA snaR expression, while GAB2 siRNA silencing significantly attenuated the enhancing effects of lncRNA snaR overexpression on cancer cell proliferation. LncRNA snaR may promote proliferation of ovarian carcinoma cells by upregulating GAB2 expression.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GRB2-associated binding protein 2; LncRNA snaR; Ovarian carcinoma; Proliferation

Mesh:

Substances:

Year:  2018        PMID: 30093110     DOI: 10.1016/j.bbrc.2018.07.152

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  GAB2 and GAB3 are expressed in a tumor stage-, grade- and histotype-dependent manner and are associated with shorter progression-free survival in ovarian cancer.

Authors:  Caglar Berkel; Ercan Cacan
Journal:  J Cell Commun Signal       Date:  2020-09-04       Impact factor: 5.782

2.  Long Non-coding RNA snaR Promotes Proliferation in EGFR Wild Type Non-Small Cell Lung Cancer Cells.

Authors:  Melika Ameli Mojarad; Mandana Ameli Mojarad; Alireza Pourmahdian
Journal:  Int J Mol Cell Med       Date:  2022-06-06

3.  A cancer-associated RNA polymerase III identity drives robust transcription and expression of snaR-A noncoding RNA.

Authors:  Kevin Van Bortle; David P Marciano; Qing Liu; Tristan Chou; Andrew M Lipchik; Sanjay Gollapudi; Benjamin S Geller; Emma Monte; Rohinton T Kamakaka; Michael P Snyder
Journal:  Nat Commun       Date:  2022-05-30       Impact factor: 17.694

4.  A noncanonical microRNA derived from the snaR-A noncoding RNA targets a metastasis inhibitor.

Authors:  Daniel Stribling; Yi Lei; Casey M Guardia; Lu Li; Christopher J Fields; Pawel Nowialis; Rene Opavsky; Rolf Renne; Mingyi Xie
Journal:  RNA       Date:  2021-04-01       Impact factor: 5.636

5.  LncRNA SNHG20 predicts a poor prognosis and promotes cell progression in epithelial ovarian cancer.

Authors:  Dandan Wang; Jianrong Dai; Shunyu Hou; Yonghong Qian
Journal:  Biosci Rep       Date:  2019-04-02       Impact factor: 3.840

6.  LINC00957 Acted as Prognostic Marker Was Associated With Fluorouracil Resistance in Human Colorectal Cancer.

Authors:  Li Hua Zhang; Long Hai Li; Peng Fei Zhang; Yan Fei Cai; Dong Hua
Journal:  Front Oncol       Date:  2019-08-21       Impact factor: 6.244

7.  LncRNA ZFAS1 serves as a prognostic biomarker to predict the survival of patients with ovarian cancer.

Authors:  Shuang Han; De-Zhan Li; Mei-Fang Xiao
Journal:  Exp Ther Med       Date:  2019-10-25       Impact factor: 2.447

8.  LncRNA-SNHG16 Silencing Inhibits Prostate Carcinoma Cell Growth, Downregulate GLUT1 Expression and Reduce Glucose Uptake.

Authors:  Mingfeng Shao; Ziqiang Yu; Jianan Zou
Journal:  Cancer Manag Res       Date:  2020-03-09       Impact factor: 3.989

9.  KPNA2-Associated Immune Analyses Highlight the Dysregulation and Prognostic Effects of GRB2, NRAS, and Their RNA-Binding Proteins in Hepatocellular Carcinoma.

Authors:  Xiuzhi Zhang; Jialing Zhang; Fenglan Gao; Shasha Fan; Liping Dai; Jinzhong Zhang
Journal:  Front Genet       Date:  2020-10-26       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.